aptaTargets presents ApTOLL at the International Oligonucleotides and Peptides Conference 2022

20 June, 2022

aptaTargets -International Oligonucleotides Conference 2022
aptaTargets will present ApTOLL, a promising therapeutic aptamer for toll-like receptor 4 (TLR4)-dependent diseases, at the International OligonucIeotides and Peptides Conference 2022 (IOPC) which takes place from 27 to 29 June in Milan (Italy).

IOPC 2022 will feature over 40 academic and industry experts as speakers, each explaining the latest innovation and trends in the oligonucleotides and peptides field.

Dr David Piñeiro, Project & CMC Manager of aptaTargets, will give the lecture on 29 June 2022 at 2:50 pm with the aim to overview about the potential of therapeutic application of ApTOLL and its development stages in the different TLR4-dependent diseases that the company is working on.

ApTOLL is an innovative single-strand DNA molecule with an antagonistic effect on TLR4 which blocks the inflammatory response. It has shown an excellent safety profile in prelinical studies for pathologies where TLR4 plays an important role (intracerebral haemorrhage, myocardial infarction and multiple sclerosis), in Phase 1a and Phase 1b/2a clinical studies for the treatment of acute ischemic stroke, and in Phase 1b trials for the treatment of COVID-19.

Within the framework of the OLIGOFASTX consortium, aptaTargets has started the development of a new aptamer for the treatment of Guillain-Barré syndrome.

For more information, please visit https://www.iopc-tks.com/agenda/